Company / R&D Expense
Cue Biopharma, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$37.7M
FY2025
5-year range
$36.3M / $41.3M
FY2021-FY2025
Trend
+4.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 8 years, ranging from $19M in FY2018 to $41M in FY2021.
Based on SEC 10-K filings.
$38M in FY2025 with a 5-year CAGR of +6.5%.
Declined from $41M to $38M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -0.7%
- 5-Year CAGR
- +6.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.5%, indicating consistent growth.
- In FY2025, r&d expense increased 4.0% year-over-year.
- Peak r&d expense was recorded in FY2021.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $37.7M | +4.0% |
| FY2024 | $36.3M | -11.0% |
| FY2023 | $40.8M | +5.8% |
| FY2022 | $38.6M | -6.7% |
| FY2021 | $41.3M | +50.4% |
| FY2020 | $27.5M | -3.7% |
| FY2019 | $28.5M | +51.0% |
| FY2018 | $18.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026